Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain
Isabel Blancas(Universidad de Granada), Walid Fakhouri(Eli Lilly (United States)), Sara Siddi(Parc Sanitari Sant Joan de Déu), Anna Emde(Eli Lilly (United States)), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Nadia Chouaki(Eli Lilly (United States)), Lucia Del Mastro(Ospedale Policlinico San Martino), Manuel Atienza(Eli Lilly (United States)), Antonella Tamma(Eli Lilly (United States)), Ghassan Sleilaty(Eli Lilly (United States)), R. Pedersini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Jessica Grosjean(Centre Hospitalier de Valenciennes), Carlotta Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Molero(Eli Lilly (United States))
Cited by 4
Related Papers
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
|Frontiers in Oncology|2018|205